georgie18
2 meses hace
SGMO...$1.45...🥳...Off my $1.03 Dip Alert...
georgie18
Member Level
Re: georgie18 post# 670316
Monday, January 06, 2025 9:52:15 AM
Post#
670503
of 670675
SGMO...$1.35s clearing here off my $1.03 Dip Alert...🥳
georgie18
Member Level
Re: georgie18 post# 996
Friday, January 03, 2025 2:29:51 PM
Post#
997
of 999
SGMO...$1.28s clearing here...🥳...Off the $1.03...Dip Alert...
georgie18
Member Level
Re: georgie18 post# 670026
Friday, January 03, 2025 8:31:17 AM
Post#
670182
of 670314
SGMO...$1.13s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 985
Thursday, January 02, 2025 9:42:07 AM
Post#
992
of 995
SGMO...$1.03...🥳...Loading down here...Took a dip... Pfizer terminated partnership...
georgie18
2 meses hace
SGMO...$1.35s clearing here off my $1.03 Dip Alert...🥳
georgie18
Member Level
Re: georgie18 post# 996
Friday, January 03, 2025 2:29:51 PM
Post#
997
of 999
SGMO...$1.28s clearing here...🥳...Off the $1.03...Dip Alert...
georgie18
Member Level
Re: georgie18 post# 670026
Friday, January 03, 2025 8:31:17 AM
Post#
670182
of 670314
SGMO...$1.13s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 985
Thursday, January 02, 2025 9:42:07 AM
Post#
992
of 995
SGMO...$1.03...🥳...Loading down here...Took a dip... Pfizer terminated partnership...
georgie18
4 meses hace
SGMO...$2.53...Fins after close...🥳
georgie18
Member Level
Re: georgie18 post# 664188
Friday, November 08, 2024 11:09:45 AM
Post#
664225
of 664553
SGMO...$3.10s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 385366
Friday, November 08, 2024 9:21:06 AM
Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...
georgie18
Member Level
Re: georgie18 post# 663989
Thursday, November 07, 2024 2:23:36 PM
Post#
664113
of 664186
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$3.10s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 385366
Friday, November 08, 2024 9:21:06 AM
Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...
georgie18
Member Level
Re: georgie18 post# 663989
Thursday, November 07, 2024 2:23:36 PM
Post#
664113
of 664186
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...
georgie18
Member Level
Re: georgie18 post# 663989
Thursday, November 07, 2024 2:23:36 PM
Post#
664113
of 664186
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Monksdream
3 semanas hace
glenn1919
2 meses hace
PonkenPlonken
2 meses hace
jimr1717
2 meses hace
jondoeuk
2 meses hace
Mactheriverrat
3 meses hace
molee
4 meses hace
INV4
4 meses hace
Hot Features
Premium
